October 3rd 2022
This week's edition of the Mainstream Patient features stories about recommended acne solutions from dermatologists, Latinx-owned beauty brands, the latest skin care trend of "skin energy," and more.
September 15th 2022
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
4th Annual International Congress on the Future of Women’s Health™
07/22/2023
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
6th Annual Advanced Practice Collaborative
09/08/2023-09/09/2023
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
HPV vaccine approval will lead to several questions
June 1st 2006Washington - A human papilloma virus (HPV) vaccine, based onnoninfectious virus-like particles, could be on the market as earlyas this summer, according to John Schiller, Ph.D., section chief,laboratory of cellular oncology, National Cancer Institute,Bethesda, Md.
Combination approach effective for wart therapy
April 1st 2006National report ? Modern goals for wart therapy are based on both lesion clearance and recurrence prevention, and achieving those objectives, especially in tough cases, usually requires a combination approach incorporating an agent that will provide antiviral and immunomodulatory activity, says Stephen K. Tyring, M.D., Ph.D.
Oral contraceptives may prevent acne, too
March 1st 2006Las Vegas ? Hormonal therapy with an estrogen-progestin oral contraceptive (OC) can be a useful adjunct for acne treatment in adult women who fail to respond to traditional topical and systemic therapies, according to Julie C. Harper, M.D., at the Fall Clinical Dermatology Conference.
Biologics may be less toxic than other medications
February 1st 2006National report - Biologic agents will not necessarily be more effective than current drugs used for dermatological conditions, but will produce less toxicities, says the professor and chairman of dermatology at Wake Forest University School of Medicine, Winston-Salem, N. C.
Melanoma diagnosis in women of childbearing age brings questions
January 1st 2006National report — One-third of women with melanoma are of childbearing age at the time of diagnosis. Dermatologists need to be prepared to answer a variety of questions regarding the impact of pregnancy on melanoma prognosis, evaluation and management, Jean L. Bolognia, M.D. says.
Counterfeit drug trade draws congressional scrutiny
December 1st 2005Counterfeit prescription drugs pose a "potentially serious health threat" in the United States — one that can result in serious or deadly consequences for patients because of unscrupulous acts of profiteers who take advantage of a lack of uniform regulation and enforcement.
Counterfeit drug trade draws congressional scrutiny
December 1st 2005Counterfeit prescription drugs pose a "potentially serious health threat" in the United States — one that can result in serious or deadly consequences for patients because of unscrupulous acts of profiteers who take advantage of a lack of uniform regulation and enforcement.
Anti-TNF-alpha agents OK in pregnancy
October 21st 2005National report — Preliminary review finds no adverse effects of anti-TNF-alpha agents on pregnancy outcomes. Analyses of limited data collected by the Organization of Teratology Information Services (OTIS) suggest there is no increased risk of major malformations or spontaneous abortions in women who received treatment with an anti-TNF-alpha medication early during pregnancy, reports Christina Chambers, Ph.D., M.P.H., who is current President of OTIS, assistant professor, departments of pediatrics and family and preventive medicine, University of California San Diego, La Jolla, Calif.
FDA approves Fraxel for melasma treatment
September 6th 2005Palo Alto, Calif. -- The Food and Drug Administration (FDA) has approved Fraxel, a skin-resurfacing laser device manufactured by Reliant Technologies, for use in the treatment of melasma associated with pregnancy, female hormonal activity and certain drugs.
Leave photography to photographers
August 1st 2005If I had wanted to be a professional photographer, I would have foregone the 10 mind-numbing years of medical school, internships and residency training, bought a camera and started clicking. As it was, I became a dermatologist, established a successful practice, bought a camera — 20 in fact — and started clicking.